Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients.

Human immunodeficiency virus (HIV) infection has become widespread among parenteral drug abusers. We measured antibody to HIV and hepatitis B virus markers in 58 long-term, socially rehabilitated methadone-maintained former heroin addicts. None of the 58 had antibody to HIV, but one or more markers of hepatitis B virus infection were seen in 53 (91%). The duration of methadone maintenance was 16.9 +/- 0.5 years, and the median dose of methadone was 60 mg (range, 5 to 100 mg). Before methadone treatment, the patients had abused heroin parenterally for 10.3 +/- 1.7 years, and they had engaged in additional high-risk practices for HIV infection. We conclude that successful outcomes during methadone maintenance treatment are associated with sparing of parenteral drug abusers from HIV infection.

[1]  N. Chiorazzi,et al.  Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. , 1989, The Journal of pharmacology and experimental therapeutics.

[2]  Samuel R. Friedman,et al.  HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. , 1989, JAMA.

[3]  S. Weiss.  Links between cocaine and retroviral infection. , 1989, JAMA.

[4]  R. Chaisson,et al.  Cocaine use and HIV infection in intravenous drug users in San Francisco. , 1989, JAMA.

[5]  V. Dole,et al.  Implications of methadone maintenance for theories of narcotic addiction. , 1988, JAMA.

[6]  M. Kreek,et al.  Hepatitis D virus and human immunodeficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive. , 1988, The Journal of infectious diseases.

[7]  S. Friedman,et al.  Reducing the risk of AIDS through methadone maintenance treatment. , 1988, Journal of health and social behavior.

[8]  D. D. Des Jarlais,et al.  Methadone maintenance patients in general medical practice. A preliminary report. , 1988, JAMA.

[9]  C. Sterk,et al.  COCAINE AND HIV SEROPOSITIVITY , 1988, The Lancet.

[10]  L. Brown,et al.  Drug treatment and HIV seropositivity. , 1988, New York state journal of medicine.

[11]  W. El-Sadr,et al.  Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. , 1987, AIDS.

[12]  E. Schiff,et al.  A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. , 1987, The New England journal of medicine.

[13]  D. Chitwood,et al.  How women and men get cocaine: sex-role stereotypes and acquisition patterns. , 1987, Journal of psychoactive drugs.

[14]  F. Sileo,et al.  AIDS in Italy. , 1987, The American journal of drug and alcohol abuse.

[15]  M. Kreek,et al.  Antibody to LAV, the putative agent of AIDS, in parenteral drug abusers and methadone-maintained patients: therapeutic, historical, and ethical aspects. , 1986, NIDA research monograph.

[16]  M. Kreek,et al.  Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection. , 1986, Bulletin on narcotics.

[17]  D. Lipton,et al.  Patterns of cocaine use among methadone clients. , 1985, The International journal of the addictions.

[18]  M. Anglin,et al.  Long-term Follow-up of Clients of High- and Low-Dose Methadone Programs: Dr McGlothlin died shortly after this article was accepted. For the field and for many colleagues it is a loss that is keenly felt.—ED. , 1981 .

[19]  L. Grönbladh,et al.  The Swedish methadone maintenance program: a controlled study. , 1981, Drug and alcohol dependence.